Lung Cancer Molecular Diagnostics
Request Sample Report
Lung Cancer Molecular Diagnostics Market Size and Growth
The Lung Cancer Molecular Diagnostics market is experiencing significant growth, driven by rising incidence rates and advancements in targeted therapies. By 2025, the market is projected to reach approximately $5 billion, reflecting a CAGR of 10%. Key factors include technological innovations, increasing awareness, and demand for personalized medicine in lung cancer treatment.
Companies Covered
(Covid 19 Impact Covered)
◍ Foundationmedicine
◍ Sansure
◍ Liferiver
◍ Roche
◍ Gpmedical
◍ Qiagen
◍ Mole
◍ Genetech
◍ Tellgen
◍ Amoydx
◍ Annoroad
The lung cancer molecular diagnostics market is competitive, featuring companies like Foundation Medicine, Roche, and Qiagen. These firms innovate through advanced genomic profiling and targeted therapies, enhancing diagnosis and treatment precision. Their contributions, including comprehensive testing solutions, foster market growth. Revenue examples include Roche's diagnostics division, which reported billions in sales.
Market Segmentation
By Application
Clinical Diagnosis
Drug Screening
Research
Request Sample Report
By Product
PCR
FISH
DNA Sequencing
Gene Chip
Market Growth
Request Sample Report
$ X Billion USD
